MRKMerck Sharp & Dohme LLCSigning up patients
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Thrombocythemia, Essential · Primary Myelofibrosis · Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-essential Thrombocythemia Myelofibrosis · Polycythemia Vera
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 400 (planned)
- Started
- May 23, 2024
- Main results expected
- Dec 4, 2034
- Fully finished
- Dec 4, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants with one or more adverse events (AEs)
Measured over: Up to ~10 years
Percentage of participants who discontinued study treatment due to an AE
Measured over: Up to ~10 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06351631 · record last updated 2026-04-02 · checked 2026-11-09 15:47 UTC